Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: True Grit who wrote (2952)	3/12/1999 2:26:00 AM
From: Regent	Respond to of 3702

The real deal is the option to pick up the VTA technology, IMHO. But at least the Company has a few bucks to cover the overhead without having to draw down on the line of credit which just dilutes everyone even more.

To: True Grit who wrote (2952)	3/12/1999 9:06:00 AM
From: shero	Read Replies (1) \| Respond to of 3702

True Grit: I don't know where you heard all that stuff about the Lym-1 trials. My info has it the we are less (way less) the 50% of enrollment. And because of the terrible protocol accepted by Alpha and TCLN the first 15 or so patients were too sick. I think most of them only received imaging doses before...well, we know what happens to high grade lympnoma patients. But at least that protocol was modified and now we can treat patients who have failed other MaB therapies. I am going to try to focus on the positive, oh, it is so hard after all these years, your point is well taken. Try on these glasses. Schering has had a chance to review all the LYM data. They coughed up $3MM, granted that is a rounding error to them, but these companies still don't throw away money. I feel Schering must think this is an approvable drug. And it does provide credibility. The 'Street' clearly didn't think a deal would get done, lets see if any institutions are willing to hear the "new" story. And your comments are, as always, welcome.